Quantcast
Last updated on April 18, 2014 at 15:05 EDT

Latest Idenix Pharmaceuticals Inc. Stories

2012-02-03 07:00:00

CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and...

2012-01-10 07:50:00

VANCOUVER, British Columbia, Jan.10, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Perfect World (NASDAQ:PWRD), Idenix Pharmaceuticals (NASDAQ:IDIX), Health Management (NYSE:HMA), Delta Air Lines (NYSE:DAL), Patriot Coal (NYSE:PCX) and Frontier Communications (NASDAQ:FTR). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to...

2012-01-09 06:01:00

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus (HCV) development pipeline. IDX719: NS5A ProgramIdenix announced today the initiation of a phase I clinical trial of the Company's NS5A inhibitor, IDX719. The first part of the study will evaluate safety,...

2012-01-09 06:00:00

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in...

2012-01-03 07:30:00

CAMBRIDGE, Mass., Jan. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that Idenix management will present a corporate overview at the 30th Annual J.P. Morgan Healthcare Conference on January 11, 2012 at 2:00 p.m. PST at the Westin St. Francis in San Francisco. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes...

2011-11-16 07:36:00

CAMBRIDGE, Mass., Nov. 16, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 9,393,416 shares of its common stock at a public offering price of $6.50 per share. All of the shares are being sold by Idenix. The offering is expected to close on November 21, 2011, subject to customary...

2011-11-02 15:05:00

CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2011. At September 30, 2011, Idenix's cash and cash equivalents totaled $64.7 million. Third Quarter and Nine Month 2011 Financial ResultsFor the third quarter ended September 30,...

2011-10-26 15:05:00

CAMBRIDGE, Mass., Oct. 26, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will report its financial results for the third quarter of 2011 on Wednesday, November 2, 2011 after U.S. financial markets close. Idenix management will host a conference call at 4:30 p.m. ET on Wednesday, November 2, 2011 to discuss the company's financial results for the third quarter of 2011 and provide an update on the company's development programs. To access the call...

2011-09-14 15:05:00

CAMBRIDGE, Mass., Sept. 14, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will present a corporate overview at the UBS Global Life Sciences Conference on September 21, 2011 at 2:00 p.m. ET at the Grand Hyatt, New York City. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the event...

2011-09-06 15:05:00

CAMBRIDGE, Mass., Sept. 6, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will present a corporate overview at the Morgan Stanley Global Healthcare Conference on September 13 at 8:35 a.m. ET at the Grand Hyatt, New York City and at the Bank of America Merrill Lynch Global Healthcare Conference on September 16, 2011 at 8:55 a.m. GMT at the Bank of America Merrill Lynch Financial Centre, London. The live and archived webcasts of the...